CALL FOR APPLICATIONS FOR CLINICAL AND LABORATORY PHD/DPHIL OR POST-DOCTORAL COVID-19 FELLOWSHIPS

The Training for Research Excellence and Mentorship in Tuberculosis (TRENT) is a consortium of the University of
Zimbabwe, the Biomedical Research Training Institute (BRTI), and the University of California, San Francisco (UCSF) to provide multi-disciplinary training to junior scientists to strengthen research capacity and promote high quality, innovative, and locally relevant HIV/TB and related research. The programme is supported by the NIH/Fogarty International Center in the United States of America. The TRENT programme invites applications for DPhil/PhD and post-doctoral fellowships who would like to focus on COVID-19 research. The fellowship is on offer for one year, with a possibility of a renewal.

For more information Click here:

Register here:

POSTPONED – SD CFAR grant due dates in 2020:<https://cfar.ucsd.edu/en/grants/>

*   International Pilot
Grants<https://cfar.ucsd.edu/en/grants/international-pilot/>:
Applications are now being accepted from emerging investigators who hold faculty-level appointments in one of seven focus countries. Priority is given to applications from Mexico and Mozambique. Applications from investigators based in Brazil, India, Kyrgyzstan, South Africa, and Ukraine are also considered. Full details on
applying for this opportunity are available on the SD CFAR website<https://cfar.ucsd.edu/en/grants/international-pilot/>.
Due date: Friday, May 1, at 5:00 pm Pacific Time. Please note we are
only accepting these applications once in 2020 due to the National
CFAR Meeting scheduled in San Diego in early November.

 

*   Developmental

grants<https://cfar.ucsd.edu/en/grants/developmental-grants/>:
Applications are now being accepted via InfoReady
Review<https://ucsd.infoready4.com/#homePage>. Emerging investigators
are encouraged to apply. Extra weight is given to applications
addressing the Ending the HIV Epidemic Initiative. Full details on
applying for this opportunity are available on the SD CFAR
website<https://cfar.ucsd.edu/en/grants/developmental-grants>.
Due date: Thursday, June 18, at 5:00 pm Pacific Time. As of now, we
are planning a second application cycle due in December 2020, after
the National CFAR Meeting.

 

RFA-DA-20-028: Implementing the HIV Service Cascade forJustice-Involved Populations (March 30,
2020):<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-20-028.html>

NIDA is interested in research that addresses research gaps related to
the delivery of integrated treatment services for HIV and opioid use
disorder (OUD) among the justice-involved population in the US, with a
goal of improving treatment management and implementation.
LOI Due Date: March 30, 2020

 

Administrative Supplements for P30 Cancer Centers Support Grants
(CCSG) to Stimulate Research in HIV/AIDS Cancer Research Projects at
NCI-designated Cancer Centers (March 31, 2020):

The National CancerInstitute (NCI) announces an opportunity for supplemental funding in
support of projects that utilize biospecimens from the AIDS and Cancer Specimen Resource (ACSR)* inventory (or another certified biorepository); data from existing cohorts; and/or biospecimens and
clinical data from the Cancer Center itself, including international partnerships of the Center. The primary goal of this initiative is to stimulate research in AIDS defining (ADCs) and non-AIDS defining cancers (NADCs) at the NCI-designated Cancer Centers (CC). This effort is aimed to expand the knowledge base of HIV/AIDS cancer pathogenesis, etiology, early detection, treatments, and cures.
Request Receipt Due: March 31, 2020
Earliest Anticipated Start Date for Awards: July 1, 2020

 

Administrative Supplements for P30 Cancer Centers Support Grants(CCSG) to Stimulate Research in Immunotherapy and Tumor Microenvironment in HIV/AIDS Cancer Patients at NCI-designated Cancer
Centers (March 31, 2020):

The National Cancer Institute (NCI) announces an opportunity for supplemental funding to identify and
advance immunotherapy translational approaches for HIV/AIDS individuals with cancer. The primary goals will be the discovery and characterization of immunotherapeutic targets, the development of new immunotherapy treatment approaches, and the improved understanding of the immunosuppressive tumor microenvironment, all in order to advance new, more effective immune-based therapeutic regimens for patients
with HIV/AIDS-related cancers.
Request Receipt Due: March 31, 2020
Earliest Anticipated Start Date for Awards: July 1, 2020

 

Administrative Supplements for P30 Cancer Centers Support Grants (CCSG) to Stimulate Research in Non-AIDS Defining Cancers (NADCs) in Aging Populations (March 31, 2020): 

The National Cancer Institute (NCI) announces an opportunity for supplemental funding to stimulate
research in non-AIDS defining cancers (NADCs) among aging HIV+ individuals via support of pilot projects at NCI-designated Cancer Centers (CC). Findings from this supplement are aimed to expand our knowledge of the impact of aging on the pathogenesis of NADCs.
Request Receipt Due: March 31, 2020
Earliest Anticipated Start Date for Awards: July 1, 2020

 

One-Year FY2020 EHE CFAR Supplement Announcement (April 2, 2020):

We are pleased to forward the One-Year FY2020 EHE CFAR Supplementopportunity. Please see important information below and the attached supplement announcement for more details on requirements. Important
Internal SD CFAR Submission Processes and Deadlines: Please submit a one-page Letter of Intent (LOI) to the SD CFAR Administrative Core(cfar@ucsd.edu<mailto:cfar@ucsd.edu>) by 12:00pm on Thursday, April 2. Attached is LOI guidance. Submitted LOIs will undergo review by SD CFAR leadership and the final four (4) proposals will be
selected for submission.

Research Topics:
·         EHE Team-initiated Implementation Research –  $200,000.Direct Costs (Maximum of 2 applications/CFAR)
·         Reaching Cisgender Heterosexual Women with PrEP – $150,000.Direct Costs (Maximum of 1 application/CFAR)
·         Evaluating and Developing Data-Driven Messages and.Communication Strategies for EHE  – $150,000 Direct Costs (Maximum of.1 application/CFAR)

In summary, a total of four (4) applications as noted above will be submitted to NIAID through the SD CFAR Administrative Core.

UC San Diego Global Health Institute Funding Opportunities (April 15,2020):

UC San Diego’s Global Health Institute (GHI) is excited to announce multidisciplinary funding opportunities for 2020. GHI is seeking proposals for three different funding opportunities:

*   Research and Travel Grants for Faculty and Postdoctoral Fellows, maximum funds $10,000/research project, $1,500/person for travel. Apply here<https://forms.gle/SjQDrDrPEcwonK2S7>.

*   Student Field Experience/Research Awards, maximum funds
$2,000/student. Apply here<https://forms.gle/xdkFkG8SU3toEbv47>.
*   Student Intern Opportunities via the Global Health Interns
Program, maximum funds $5,000/team. Apply
here<https://forms.gle/RaUboqQ4KhPSXkMx7>.

NIH Funding Opportunity: RFA-CA-20-016: HIV/AIDS and the Tumor Niche
(U54 Clinical Trial Not

Allowed):<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-016.html> The purpose of this Funding Opportunity Announcement (FOA) is to advance our understanding of the role of the tumor niche or microenvironment in the risks, development, progression, and diagnosis
of cancer observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS). LOI due date: 30 days prior to application due date (March 15, 2020)
Application due date: April 15, 2020

 

UC Multicampus Research Programs and Initiatives (MRPI) RFP (April 22,2020):

UC Research Initiatives in the UC Office of the President is pleased to issue the UC Multicampus Research Programs and Initiatives.Request for Proposals for award year 2021. This Request forProposals<https://ucop.edu/research-initiatives/programs/mrpi/2021mrpirfp.pdf> includes opportunities for both 2-year Planning/Pilot Awards and
multiyear Program Awards. The MRPI opportunity is open to UC faculty and researchers in any field of research and scholarship. LOI due date: April 22, 2020

Notice of Special Interest: NOT-CA-20-022:

Use of Biological “High” or”Medium” Priority AIDS Research on Non-AIDS-defining or AIDS-defining
Cancers:<https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-022.html> The purpose of this Notice of Special Interest (NOSI) is to continue advancing our understanding of the risks, development, progression,
diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals.First Available Due Date: May 7, 2020

 

NIH Funding Opportunity: RFA-OD-19-029, The Intersection of Sex and Gender Influences on Health and Disease (November 25,
2020):

<https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-19-029.html> Invites research applications that examine sex and gender factors and their intersection in understanding health and disease; and research
that addresses one of the five objectives from Strategic Goal 1 of the new 2019-2023 Trans-NIH Strategic Plan for Women’s Health Research “Advancing Science for the Health of Women.”
Application due date: November 25, 2020

 

NIH Funding Opportunity: NOT-OD-20-049, Notice of Special Interest:Administrative Supplements for Research on Sex/Gender Influences(January 25, 2021):

<https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-049.html>
One-year supplements limited to $100K direct costs. Supports preclinical and/or clinical research and must include either adding the opposite sex/gender, increasing sample size, or analyzing existing data to investigate the role of sex/gender. Parent grant must have 16 months remaining from the due date Application due date: January 25, 2021

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV) (February 6,2021):

<https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-030.html> NIAID and NIGMS are issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (2019-nCoV). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as
projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV. NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens.
Applications in response to this NOSI must be submitted using the PA-18-935 Funding Opportunity<https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html>.Expiration Date: February 6, 2021

 

Funding for Fellows: Next Generation

Grants<https://cfar.ucsd.edu/en/grants/next-generation/>SD CFAR’s Next Generation grants are designed for postdoctoral fellows supported by T32, D43, and R25 awards. These grants provide critical funds to help fellows collect and analyze data in support of their CDA applications. Up to $10,000 in direct costs may be requested for a
one-year Next Generation grant. View all of the details and download an application form here<https://cfar.ucsd.edu/en/grants/next-generation/>.

 

Non-NIH Funding

Opportunities:<https://cfar.ucsd.edu/en/news-events/non-nih-funding-opportunities/> In addition to NIH, many public and private organizations support HIV research. If you are interested in exploring other funding sources for
your HIV projects, check out our other Non-NIH Funding Opportunities<https://cfar.ucsd.edu/en/news-events/non-nih-funding-opportunities/>on the SD CFAR website.

SD CFAR grant due dates in 2020: International Pilot grants will be accepted only once this year on Wednesday, April 1. We are not scheduling an October cycle due to the National CFAR Meetings in San Diego in early November. The next due date for Developmental grants is Monday, May 18, because the review committee can only meet in early June. Please note these dates. Additional announcements will follow, and you are always welcome to email questions to cfar@ucsd.edu.

 

NIH Funding Opportunity: RFA-CA-20-016: HIV/AIDS and the Tumor Niche (U54 Clinical Trial Not Allowed):

The purpose of this Funding Opportunity Announcement (FOA) is to advance our understanding of the role of the tumor niche or microenvironment in the risks, development, progression, and diagnosis of cancer observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS).

LOI due date: 30 days prior to application due date

Application due date: April 15, 2020.

 

Notice of Special Interest: NOT-CA-20-022: Use of Biological “High” or “Medium” Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers: The purpose of this Notice of Special Interest (NOSI) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals.

First Available Due Date: May 7, 2020

1. Immunotherapy and Tumor Microenvironment in HIV/AIDS Cancer Patients

The National Cancer Institute (NCI) announces an opportunity for supplemental funding to identify and advance immunotherapy translational approaches for HIV/AIDS individuals with cancer. The primary goals will be the discovery and characterization of immunotherapeutic targets, the development of new immunotherapy treatment approaches, and the improved understanding of the immunosuppressive tumor microenvironment, all in order to advance new, more effective immune-based therapeutic regimens for patients with HIV/AIDS-related cancers.

2.Non-AIDS Defining Cancers (NADCs) in Aging Populations – The National Cancer Institute (NCI) announces an opportunity for supplemental funding to stimulate research in non-AIDS defining cancers (NADCs) among aging HIV+ individuals via support of pilot projects at NCI-designated Cancer Centers (CC). Findings from this supplement are aimed to expand our knowledge of the impact of aging on the pathogenesis of NADCs.

3.     HIV/AIDS Cancer Research Projects (Bio Cohort)

The National Cancer Institute (NCI) announces an opportunity for supplemental funding in support of projects that utilize biospecimens from the AIDS and Cancer Specimen Resource (ACSR) inventory (or another certified biorepository); data from existing cohorts; and/or biospecimens and clinical data from the Cancer Center itself, including international partnerships of the Center. The primary goal of this initiative is to stimulate research in AIDS defining (ADCs) and non-AIDS defining cancers (NADCs) at the NCI-designated Cancer Centers (CC).

 

 

 

NIH Funding Opportunity: RFA-AI-19-067: Digital, Limited Interaction Trials and Epidemiology (D-LITE): Targeting HIV Incidence in the United States (U01 Clinical Trial Required): The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to conduct large-scale digital clinical trials to test whether digitally-delivered HIV prevention interventions can reduce HIV incidence among U.S. men who have sex with men (MSM) and/or transgender women and men.

LOI due date: February 20, 2020

Application due date: March 20, 2020

 

Funding for Fellows: Next Generation Grants

SD CFAR’s Next Generation grants are designed for postdoctoral fellows supported by T32, D43, and R25 awards. These grants provide critical funds to help fellows collect and analyze data in support of their CDA applications. Up to $10,000 in direct costs may be requested for a one-year Next Generation grant. View all of the details and download an application form here.

Seeking Applications for the 2nd Annual Dr. Eddie Mendez Scholars Award (February 14, 2020): The Dr. Eddie Mendez Scholars Award recognizes outstanding postdoctoral fellows from any discipline who are conducting research related to cancer, HIV, or other infectious diseases. The award was created to recognize Dr. Méndez’s commitment to cancer research and to supporting early-career underrepresented minority scientists and scientists with disabilities. Awardees will present at a scientific symposium on May 21-22, 2020 honoring Dr. Eddie Mendez and will have the opportunity to visit Fred Hutch and meet with faculty members.  The deadline to apply is February 14, 2020Application: https://apply.interfolio.com/69916. Contact Ana Parada with any questions.

Funding Opportunity Announcement RFA-DK-19-019 (March 9, 2020): The “Food as Medicine: Food Insecurity and HIV-related Comorbidities, Coinfections, and Complications within the Mission of the NIDDK (R01 Clinical Trial Optional)” funding opportunity announcement (FOA) seeks US domestic research projects that address how food insecurity affects HIV comorbidities, coinfections, and complications (CCCs) within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The approaches may address the pathways linking food insecurity and the development or exacerbation of CCCs; or they may evaluate the mechanisms whereby interventions that alleviate food insecurity improve CCCs. These mechanisms could be related to nutritional inadequacies or patient health-related behaviors.

Open Date: February 9, 2020

LOI Due Date: February 9, 2020

Application Due Date: March 9, 2020

NIH Funding Opportunity: RFA-DA-20-022: Assessing the Effects of Cannabinoids on HIV-Induced Inflammation (R01 Clinical Trial Optional): The purpose of this Funding Opportunity Announcement (FOA) is to encourage basic science and preclinical research to determine the biological mechanisms underlying the effects of cannabinoids and the endocannabinoid system on HIV-associated persistent inflammation and its consequent effects on nervous system function.
LOI due date: February 11, 2020
Application due date: March 11, 2020